Bayesian Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Bayesian Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,700	Closed	-$502K	–	602
2025 Q1	$502K	Buy	+20,700	New	+$466K	0.08%	293
2024 Q4	–	Sell	-14,741	Closed	-$293K	–	734
2024 Q3	$293K	Buy	+14,741	New	+$273K	0.03%	482
2024 Q2	–	Sell	-23,400	Closed	-$373K	–	806
2024 Q1	$373K	Buy	+23,400	New	+$353K	0.04%	505
2020 Q2	–	Sell	-12,003	Closed	-$46K	–	564
2020 Q1	$46K	Buy	+12,003	New	+$49.3K	0.01%	731
2019 Q3	–	Sell	-27,100	Closed	-$104K	–	542
2019 Q2	$104K	Buy	+27,100	New	+$117K	0.02%	460

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bayesian Capital Management's CPRX Position: Q2 2025 in Review

Bayesian Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 20,700 shares — an estimated $502K sold.

Bayesian Capital Management first reported a position in CPRX in Q2 2019 and held it in 5 quarters. The position peaked at $502K in Q1 2025. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

Bayesian Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Bayesian Capital Management sold 20,700 Catalyst Pharmaceutical shares in Q2 2025, an estimated $502K.
Bayesian Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2019 and held it in 5 quarters.
Bayesian Capital Management's Catalyst Pharmaceutical position peaked at $502K in Q1 2025.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.